Stacy Ku

David Amsellem

Jack Padovano

Kristen Kluska

Alex Riesemann

Andrew Tsai

John Cox

Lin Tsai

- Supernus Pharmaceuticals is in a **re-accelerated growth phase** following the acquisition of Sage, focusing on its CNS portfolio, which includes Qelbree, Gocovri, Onapgo, and ZURZUVAE.  **[1356576_tx_380775_0]** 
- **Qelbree**, a non-stimulant ADHD treatment, is experiencing strong growth, with recent growth rates of **25-26%**.  **[1356576_tx_380775_2]**  The adult segment now accounts for **35%** of its business, and the company believes it has significant growth potential, aiming for **4-6%** market share from its current less than **1-2%**.  **[1356576_tx_380775_2]** 
- The recently launched Parkinson's drug, **Onapgo**, a continuous apomorphine infusion device, has shown encouraging early uptake.  **[1356576_tx_380775_3]**  While initially estimated at **$200-$300 million** peak sales, its potential could be significantly larger if adopted for earlier-stage patients.  **[1356576_tx_380775_3]** 
- **ZURZUVAE**, acquired through the Sage acquisition, is the first oral medication approved for postpartum depression, a condition affecting **1 in 7** women.  **[1356576_tx_380775_3]**  Supernus is focusing on increasing disease awareness and screening among healthcare providers and patients to address the current low diagnosis rates.  **[1356576_tx_380775_4]** **[1356576_tx_380775_5]**

SUPERNUS PHARMACEUTICALS (SUPN)